AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Celcuity shares surge 13% on Phase 3 trial results; 20 stocks moving in pre-market trading.
ByAinvest
Monday, Jul 28, 2025 5:46 am ET1min read
Celcuity shares rose 12.6% in pre-market trading after announcing topline results from the Phase 3 VIKTORIA-1 trial. Other gainers include CEA Industries, Mill City Ventures, and Anghami, while losers include Sidus Space, 180 Life Sciences, and Zooz Power.
Celcuity Inc. (NASDAQ:CELC) shares surged 12.6% in pre-market trading on July 2, 2025, following the announcement of topline results from the Phase 3 VIKTORIA-1 trial. The trial, which evaluated gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer, showed promising results that have significantly boosted investor confidence in the company's oncology pipeline [1].The Minneapolis-based biotechnology company will host a conference call and webcast on July 28, 2025, at 8:00 AM ET to discuss the trial outcomes in detail. Analysts maintain a strong buy consensus on Celcuity stock, with price targets ranging from $27 to $33, reflecting the optimism around the potential of gedatolisib as a standard-of-care treatment in the metastatic breast cancer landscape [2].
Gedatolisib, Celcuity's lead therapeutic candidate, is a pan-PI3K and mTORC1/2 inhibitor that blocks the PAM pathway, differentiating itself from other approved and investigational therapies targeting similar pathways. The company's Phase 3 clinical trials, VIKTORIA-1 and VIKTORIA-2, aim to establish gedatolisib as a first-line treatment option for HR+/HER2- advanced breast cancer patients [3].
The positive pre-market reaction to the VIKTORIA-1 trial results underscores the market's belief in Celcuity's ability to deliver innovative cancer treatments. The company's stock price increase also comes amid a broader market environment where other gainers include CEA Industries, Mill City Ventures, and Anghami, while losers include Sidus Space, 180 Life Sciences, and Zooz Power.
References:
[1] https://www.stocktitan.net/news/CELC/celcuity-to-announce-topline-results-for-the-pik3ca-wild-type-cohort-1zd03ouzao4t.html
[2] https://www.investing.com/news/company-news/celcuity-to-announce-phase-3-viktoria1-trial-results-on-monday-93CH-4153939
[3] https://www.investing.com/news/stock-market-news/celcuity-stock-jumps-ahead-of-pivotal-breast-cancer-trial-results-93CH-4153899
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet